Sandbox g19: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 11: | Line 11: | ||
::* '''Otitis media, mastoiditis, or sinusitis''' | ::* '''Otitis media, mastoiditis, or sinusitis''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or [[Ceftriaxone]] 4 g/day q12h {{and}} [[Metronidazole]] 30 mg/kg/day q6h | ::::* ([[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h) {{and}} [[Metronidazole]] 30 mg/kg/day q6h | ||
::* '''Dental infection''' | ::* '''Dental infection''' | ||
| Line 46: | Line 46: | ||
::* '''Mycobacterium tuberculosis coverage''' | ::* '''Mycobacterium tuberculosis coverage''' | ||
:::* Preferred regimen | |||
::::* [[Isoniazid]] 300 mg qd {{and}} [[Rifampin]] 600 mg qd {{and}} [[Pyrazinamide]] 15–30 mg qd {{and}} [[Ethambutol]] 15 mg/kg/day qd | ::::* [[Isoniazid]] 300 mg qd {{and}} [[Rifampin]] 600 mg qd {{and}} [[Pyrazinamide]] 15–30 mg qd {{and}} [[Ethambutol]] 15 mg/kg/day qd | ||
Revision as of 05:09, 5 June 2015
Brain abscess
- Empiric antimicrobial therapy
- Brain abscess in otherwise healthy patients
- Preferred regimen
- Cefotaxime 8–12 g/day IV q4–6h OR Ceftriaxone 4 g/day IV q12h AND Metronidazole 30 mg/kg/day IV q6h
- Alternative regimen
- Meropenem 6 g/day IV q8h
- Brain abscess with comorbidities
- Otitis media, mastoiditis, or sinusitis
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Metronidazole 30 mg/kg/day q6h
- Dental infection
- Preferred regimen
- Penicillin G 24 MU q4h AND Metronidazole 30 mg/kg/day q6h
- Penetrating trauma or post-neurosurgy
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Vancomycin 30–45 mg/kg/day q8–12h
- Lung abscess, empyema, or bronchiectasis
- Preferred regimen
- Penicillin G 24 MU q4h AND Metronidazole 30 mg/kg/day q6h AND TMP-SMZ 10–20 mg/kg/day q6–12h
- Bacterial endocarditis
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h AND Gentamicin 5 mg/kg/day IV q8h
- Congenital heart disease
- Preferred regimen
- Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h
- Transplant recipients
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Metronidazole 30 mg/kg/day q6h AND Voriconazole 8 mg/kg/day q12h AND (TMP-SMZ 10–20 mg/kg/day q6–12h OR Sulfadiazine 4–6 g/day q6h)
- Patients with HIV/AIDS
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Sulfadiazine 4–6 g/day q6h AND Pyrimethamine 25–100 mg/day qd
- Staphylococcus aureus coverage
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h
- Mycobacterium tuberculosis coverage
- Preferred regimen
- Isoniazid 300 mg qd AND Rifampin 600 mg qd AND Pyrazinamide 15–30 mg qd AND Ethambutol 15 mg/kg/day qd